Stay updated with breaking news from Stage Development Programs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Company well-positioned for further progress and broadening of R&D pipelineCash resources of approximately $455 million as of December 31, 2023 Expected cash runway, including proceeds from recent...
Poseida Therapeutics Reports Program Updates and Financial Results for the First Quarter 2021 News provided by Share this article Share this article SAN DIEGO, May 11, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced program updates and financial results for the first quarter ended March 31, 2021. "We are encouraged by our continued progress in first quarter of 2021, building on the accomplishm...